Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
Clinical trial NCT05218889 · RECRUITING
Trial details
- NCT number
- NCT05218889
- Sponsor
- Chinese PLA General Hospital
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-04
- Primary completion
- 2024-12-16
- Enrollment
- 90
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.